LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Benzer Materyaller

• 1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab
  Yazar:: Richard A Furie, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)
• Targeting DORIS Remission and LLDAS in SLE: A Review
  Yazar:: Agner R. Parra Sánchez, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-10-01)
• Correction: Targeting DORIS Remission and LLDAS in SLE: A Review
  Yazar:: Agner R. Parra Sánchez, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-06-01)
• 22 New and approved therapies for SLE: Anifrolumab
  Yazar:: Ronald van Vollenhoven
  Baskı/Yayın Bilgisi: (2022-04-01)
• 06 Approved biologics for SLE: which to try first and in which patients? – The case for anifrolumab
  Yazar:: Eric Morand
  Baskı/Yayın Bilgisi: (2023-09-01)